Elanco升级，Zoetis在Piper Sandler降级

2026-01-23 00:10

Piper Sandler upgraded Elanco Animal Health (ELAN) to overweight from neutral citing inroads it has made in corporate accounts.
The firm also downgraded Zoetis (ZTS) to neutral from overweight saying that the present consumer spending environment is not conducive for the company.
The firm upped its Elanco price target to $30 from $24 (~23% upside based on Jan. 21 close). For Zoetis, the target was cut to $135 to $190 (~8% upside).
Analyst David Westenberg noted that "some of the [corporate] accounts told us Elanco will move all the way up to number two on who they want to work with," adding that there was little pushback on the idea the company will raise prices on Befrena (tirnovetmab), its treatment for itching associated with canine allergic and atopic dermatitis.
For Zoetis, it has "by far the best portfolio of products in animal health Rx, and we believe this will be true for another ten years," Westernberg added. "Saying that, the company is in an innovation air pocket that could last one to two years."

More on Elanco